The incidence rate of NAION was 123 per 100,000 person-years among semaglutide initiators and 67 per 100,000 person-years among comparator patients
However, there is limited evidence on the potential risks in patients with pre-existing gastrointestinal disease such as diverticulosis or on rare complications like hepatic abscesses [8-10]
Estrogen-responsive element (ERE) in the Nrf2 promoter region can also be directly activated by ER to promote Nrf2 transcription [190]
Common side effects include: Headache Stomach pain Diarrhea Indigestion Severe side effects may include: Allergic reactions (hives, facial swelling, shortness of breath) Heart attack, stroke, or blood clots GI ulcers, bleeding, or perforations Liver damage or elevated enzymes High blood pressure or heart failure Kidney damage Severe skin reactions (rash, blisters, peeling) These are not all possible side effects